Pafuramidine

Summary

Pafuramidine (CHEMBL319669) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 364.4 Da · C20H20N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL319669
Name	Pafuramidine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5480200
Molecular formula	C20H20N4O3
Molecular weight	364.4
InChIKey	UKOQVLAXCBRRGH-UHFFFAOYSA-N

SMILES: CO/N=C(\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N

IUPAC name: N’-methoxy-4-[5-[4-[(Z)-N’-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide

Also known as: Pafuramidina, Pafuramidine, pafuramidine, PAFURAMIDINE, C0088434

Parent form; salt/anhydrous children: CHEMBL2107359, CHEMBL4103116

Patent coverage: 29 distinct patent families (53 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 40 (75%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).